(12) **Translation of European patent specification**

(11) **NO/EP 2708559 B1**

NORWAY

(19) NO

(51) Int Cl.

C07K 16/28 (2006.01)
A61K 39/00 (2006.01)
C07K 16/24 (2006.01)
C12N 15/10 (2006.01)
G01N 33/15 (2006.01)
G01N 33/50 (2006.01)
G01N 33/68 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2018.07.23
(80)	Date of The European Patent Office Publication of the Granted Patent	2018.03.28
(86)	European Application Nr.	13195718.5
(86)	European Filing Date	2009.04.10
(87)	The European Application's Publication Date	2014.03.19
(30)	Priority	2008.04.11, JP, 2008104147 2008.09.26, JP, 2008247713 2009.03.19, JP, 2009068744
(84)	Designated Contracting States:	AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; TR
	Designated Extension States:	AL BA RS
(62)	Divided application	EP2275443, med inndato 2009.04.10
(73)	Proprietor	Chugai Seiyaku Kabushiki Kaisha, 5-1, Ukima 5-chome, Kita-kuTokyo 115-8543, JP-Japan
(72)	Inventor	IGAWA, Tomoyuki, c/o Chugai Seiyaku Kabushiki Kaisha 135 Komakado 1-chome, Gotenba-shi, Shizuoka 412-8513, JP-Japan ISHII, Shinya, c/o Chugai Seiyaku Kabushiki Kaisha 135 Komakado 1-chome, Gotenba-shi, Shizuoka 412-8513, JP-Japan MAEDA, Atsuhiko, c/o Chugai Seiyaku Kabushiki Kaisha 135 Komakado 1-chome, Gotenba-shi, Shizuoka 412-8513, JP-Japan NAKAI, Takashi, c/o Chugai Seiyaku Kabushiki Kaisha 135 Komakado 1-chome, Gotenba-shi, Shizuoka 412-8513, JP-Japan
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 2003 Vika, 0125 OSLO, Norge

(54) Title **ANTIGEN-BINDING MOLECULE CAPABLE OF BINDING TO TWO OR MORE ANTIGEN MOLECULES REPEATEDLY**

(56) References Cited:

WO-A1-2009/139822, CASIM A SARKAR ET AL: "Rational cytokine design for increased lifetime and enhanced potency using pH-activated histidine switching", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 20, no. 9, 1 September 2002 (2002-09-01), pages 908-913, XP002657852, ISSN: 1087-0156, DOI: 10.1038/NBT725 [retrieved on 2002-08-05], WO-A2-2011/111007, US-A1- 2003 059 937, MAEDA K ET AL: "pH-dependent receptor/ligand dissociation as a determining factor for intracellular sorting of ligands for epidermal growth factor receptors in rat hepatocytes", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 82, no. 1, 18 July 2002 (2002-07-18), pages 71-82, XP004369791, ISSN: 0168-3659, DOI: 10.1016/S0168-3659(02)00126-8, FREDERICK R MAXFIELD & TIMOTHY E MCGRAW: "Endocytic recycling", NATURE REVIEWS MOLECULAR CELL BIOLOGY, NATURE PUBLISHING, GB, vol. 5, no. 2, 1 February 2004 (2004-02-01), pages 121-132, XP009151548, ISSN: 1471-0072, MEGAN L. MURTAUGH ET AL: "A combinatorial histidine scanning library approach to engineer highly pH-dependent protein switches", PROTEIN SCIENCE, vol. 20, no. 9, 1 September 2011 (2011-09-01), pages 1619-1631, XP055011183, ISSN: 0961-8368, DOI: 10.1002/pro.696, IGAWA T ET AL: "Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 28, no. 11, 1 November 2010 (2010-11-01), pages 1203-1207, XP009153598, ISSN: 1087-0156, DOI: 10.1038/NBT.1691, T. IGAWA ET AL: "Reduced elimination of IgG antibodies by engineering the variable region", PROTEIN ENGINEERING DESIGN AND SELECTION, vol. 23, no. 5, 1 May 2010 (2010-05-01), pages 385-392, XP055003115, ISSN: 1741-0126, DOI: 10.1093/protein/gzq009, IGAWA TOMOYUKI ET AL: "Engineering the variable region of therapeutic IgG antibodies", MABS, LANDES BIOSCIENCE, US, vol. 3, no. 3, 1 May 2011 (2011-05-01), pages 243-252, XP009153597, ISSN: 1942-0870, ITO W ET AL: "The His-probe method: effects of histidine residues introduced into the complementary-determining regions of antibodies on antigen-antibody interactions at different pH values", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 309, no. 1, 1 August 1992 (1992-08-01), pages 85-88, XP008123385, ISSN: 0014-5793, MARTIN W L ET AL: "Crystal Structure at 2.8A of an FcRn/Heterodimeric Fc Complex: Mechanism of pH-Dependent Binding", MOLECULAR CELL, CELL PRESS, CAMBRIDGE, MA, US, vol. 7, 1 April 2001 (2001-04-01), pages 867-877, XP003027710, ISSN: 1097-2765, DOI: 10.1016/S1097-2765(01)00230-1, Andrew W Drake ET AL: "Biophysical Consideration for Development of Antibody-Based Therapeutics" In: "Biophysical Consideration for Development of Antibody-Based Therapeutics", 1 January 2012 (2012-01-01), XP055100977, pages 95-97, * the whole document *, LEE C V ET AL: "High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 340, no. 5, 23 July 2004 (2004-07-23) , pages 1073-1093, XP002716293, ISSN: 0022-2836, DOI: 10.1016/J.JMB.2004.05.051, WO-A2-03/105757

Patentkrav

1. Fremgangsmåte for å fremstille en farmasøytisk sammensetning omfattende antistoffet som isoleres ved screening-fremgangsmåten, omfattende trinnene:
(a) å bestemme den antigenbindende aktiviteten til et antistoff ved pH 6,7 til pH 10,0;
(b) å bestemme den antigenbindende aktiviteten til antistoffet ved pH 4,0 til pH 6,5; og
(c) å velge antistoffet hvis antigenbindende aktivitet ved pH 6,7 til pH 10,0 er høyere enn den antigenbindende aktiviteten ved pH 4,0 til pH 6,5;
og å formulere antistoffet valgt i trinn (c) til en farmasøytisk sammensetning.

2. Fremgangsmåte for å fremstille en farmasøytisk sammensetning omfattende antistoffet som isoleres ved screening-fremgangsmåten, omfattende trinnene:
(a) å binde et antistoff til et antigen under en betingelse ved en fra pH 6,7 til pH 10,0;
(b) å plassere antistoffet bundet til antigenet i (a) under en betingelse ved en fra pH 4,0 til pH 6,5; og
(c) å oppnå antistoffet som dissosierer under betingelsen ved en fra pH 4,0 til pH 6,5;
og å formulere antistoffet oppnådd i trinn (c) til en farmasøytisk sammensetning.

3. Fremgangsmåte for å fremstille en farmasøytisk sammensetning omfattende antistoffet som isoleres ved screening-fremgangsmåten, omfattende trinnene:
(a) å binde et antistoff til en antigenimmobilisert søyle under en betingelse ved en fra pH 6,7 til pH 10,0;
(b) å eluere antistoffet bundet til søylen under betingelse ved en fra pH 6,7 til pH 10,0 fra kolonnen under en betingelse ved en fra pH 4,0 til pH 6,5; og
(c) å samle inn det eluerte antistoffet;
og å formulere antistoffet samlet opp i trinn (c) til en farmasøytisk sammensetning.